Evan Seigerman gives his take on biotech and the CMS list, Lilly, Amgen, Skyscraper-01, Structure Therapeutics, Disc Medicine and Replimune.

Dr. Levine talks about emerging technology trends that might improve CAR-T therapies on the six-year anniversary of the first approved CAR-T

Matt Phipps gives his take on biotech and discusses Amgen, Genmab, JNJ, Merus, Janux, Autolus, Agenus, and Ikena.

Yaron Werber gives his take on biotech and discusses Legend, 2seventy bio, Arrowhead, Stoke, argenx, Immunovant, Roivant, and Springworks.

Rep. Auchincloss discusses the IRA, PBMs, funding for basic research, and other policies that affect the biotech community in his district.

ustin Zelin gives his take on biotech and discusses Viking Therapeutics, 89bio, Syndax, Kura Oncology, Poseida, and ProKidney.

Michael Yee gives his take on biotech and discusses Vertex, Ventyx Biosciences, ALX Oncology, Akero, and Prothena.

Steve Pearson walks us through the potential demand and accessibility dynamics of these key gene therapy launches.

Umer Raffat gives his take on biotech and discusses Apellis, Teva, Gilead, Vaxcyte, and Bausch Health.

Salim Syed gives his take on biotech and discusses BridgeBio, Cytokinetics, Wave Life Sciences, and Atara Biotherapeutics.

Citi's Neena Bitritto-Garg gives her take on the current state of biotech and recent news about Roivant, Prothena, Amylyx, and Sage.

Christine Brennan, Managing Director of Vertex Ventures HC, highlights neuroscience and other areas of interest in today’s biotech landscape

Brian Skorney discusses biotech's first half of 2023 and recent news from Sarepta, Regeneron, AstraZeneca, Vertex, and Biogen.

Sarah Emond was named president-elect of ICER. She explains her view of ICER’s role and where she sees drug pricing headed in the future.

Anirban Maitra and Shubham Pant from MD Anderson tell us what targets and approaches look promising in pancreatic cancer.

Dr. Jack West walks us through what lung cancer data he is interested in seeing at #ASCO23.

Paul Rennert of Aleta Biotherapeutics gives a rundown on the latest in cell therapies and other modalities ahead of #ASCO23.

Evaluate Vantage's Jacob Plieth previews what to watch for at the 2023 ASCO Annual Meeting in Chicago.

Current BIO Chairman and Nkarta CEO Paul Hastings talks about the policy changes that have been affecting biotech lately, and NK cells.

Dark Horse Consulting's Anthony Davies discusses CMC issues to consider when developing cell and gene therapies.